Pfizer (NYSE:PFE) Inc said that nearly three times as many patients receiving Selzentry, in addition to an optimised background regimen, achieved undetectable levels of HIV virus compared with those receiving an optimised regimen alone.
'These data continue to demonstrate that Selzentry provides significant benefit to certain treatment-experienced patients,' said Dr Jacob Lalezari, director, Assistant Clinical Professor of Medicine at the University of California, San Francisco.
'The safety and durability of response seen with Selzentry out to one year in our study is reassuring. This drug is an important new weapon for clinicians who treat HIV,' he added.
Results from the planned 48-week analysis also demonstrated that Selzentry, along with an optimised background regimen, significantly increased CD4 cells, as compared to patients receiving an optimised regimen alone read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment